重组人干扰素α 2b喷雾剂治疗儿童流行性感冒的疗效及安全性评价

doi:10.3969/j.issn.1000-8535.2022.05.015

摘要/Abstract

摘要： 目的探讨重组人干扰素α2b喷雾剂治疗儿童流行性感冒的疗效及安全性。方法选取我院2017年1月—2020年2月所收治的80例儿童流行性感冒患者,按1:1随机分为实验组及对照组,每组患儿40例,对照组患者给予奥司他韦治疗,实验组患者在对照组治疗基础上联合重组人干扰素α2b喷雾剂治疗,对比2组患者的疗效及安全性。结果实验组患儿咽痛症状消失时间(2.01±0.23)d、体温恢复正常时间(2.18±0.30)d、咳嗽症状消失时间(1.68±0.52)d、治疗时间(5.41±0.36)d均短于对照组(t=26.001、9.766、19.277、28.089,P＜0.05);实验组患儿治疗有效率95.0%高于对照组治疗有效率(χ²=4.114,P＜0.05);实验组患儿的不良反应发生率低于对照组(χ²=4.021,P＜0.05)。结论重组人干扰素α2b喷雾剂治疗儿童流行性感冒的方案可获取较为理想的治疗效果,保证患儿用药安全性,尽快缓解患儿的临床症状,促使患儿病情康复,促进患儿健康生长,该治疗方案可在临床中推广应用。

关键词: 重组人干扰素α2b喷雾剂, 儿童流行性感冒, 疗效, 安全性

Abstract: Objective To explore the efficacy and safety of recombinant human interferon α2b spray in the treatment of influenza in children. Methods Eighty children with influenza who were admitted to our hospital from January 2017 to February 2020 were randomly divided into experimental group and control group evenly, with 40 children in each group. Oseltamivir treatment was given to the control group, the experimental group was treated with recombinant human interferon α2b spray on the basis of oseltamivir, and the efficacy and safety of the two groups were compared. Results In the experimental group, the time for the disappearance of sore throat was (2.01±0.23) d, the time for the body temperature returned to normal was (2.18±0.30) d, the time for the cough to disappear was (1.68±0.52) d, and the treatment time was (5.41±0.36) d, which were all shorter than the control group (t=26.001, 9.766, 19.277, 28.089, P<0.05). The treatment effective rate of children in the experimental group was 95.0%, which was significantly higher than that in the control group (χ²=4.114, P<0.05); the incidence of adverse reactions in experimental group was significantly lower than that in the control group (χ²= 4.021, P<0.05). Conclusions The recombinant human interferon α2b spray for the treatment of influenza in children could obtain a more ideal therapeutic effect, ensure the safety of the children's medication, relieve the clinical symptoms as soon as possible, promote the improvement of the children's condition, and promote the healthy growth of the children. The treatment plan can be promoted and applied in clinical practice.

Key words: recombinant human interferon α2b spray, influenza in children, efficacy, safety

黎子武, 梁林国, 杨均秀, 陈强锋, 郑志坚. 重组人干扰素α 2b喷雾剂治疗儿童流行性感冒的疗效及安全性评价[J]. 广州医药, 2022, 53(5): 76-79.

LI Ziwu, LIANG Linguo, YANG Junxiu, CHEN Qiangfeng, ZHENG Zhijian. Efficacy and safety evaluation of recombinant human interferon α2b spray in the treatment of influenza in children[J]. Guangzhou Medical Journal, 2022, 53(5): 76-79.

参考文献

[1] 中华人民共和国国家卫生和计划生育委员会. 流行性感冒诊疗方案(2018年版)[J]. 中华临床感染病杂志, 2018, 11(1):1-5.
[2] 孙洪梅. 重组人干扰素α-1b雾化吸入治疗毛细支气管炎的疗效观察[J]. 中国妇幼保健, 2017, 32(22): 5647-5649.
[3] 侯云德, 张国成. 重视重组人干扰素α1b的创新研究和儿科临床应用[J]. 中华实用儿科临床杂志, 2018, 33(18): 1361-1365.
[4] 郝云涛, 郑小影, 赵淑敏,等. 重组人干扰素α2b阴道泡腾胶囊结合射频消融术治疗宫颈糜烂合并HPV亚临床感染的临床观察[J]. 中国药房, 2017, 28(23):3223-3226.
[5] 李文辉, 贾彬, 刘俊莹. 重组干扰素α-2b雾化治疗小儿毛细支气管炎的疗效及对免疫功能的影响[J]. 中国现代医学杂志, 2020,30(2):50-54.
[6] 陈海哨, 陈雪夏, 周俊,等. 重组人干扰素α-2b喷雾剂对手足口病患儿免疫功能的影响[J]. 中华医院感染学杂志, 2019, 29(10):1562-1566.
[7] 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 7版. 北京: 人民卫生出版社, 2007: 1199-1200.
[8] SHIBATA N, KIMURA S, HOSHINO T, et al. Effectiveness of influenza vaccination for children in Japan: Four-year observational study using a large-scale claims database [J]. Vaccine, 2018, 36(20): 2809-2815.
[9] SHAH K, CHAN L W, WONG T W. Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment [J]. Drug Deliv, 2017, 24(1): 1631-1647.
[10] 任吟莹,黄莉,王美娟, 等. 儿童呼吸道人副流感病毒感染临床特征及流行病学特点[J].中华实用儿科临床杂志,2017,32(4):270-274.
[11] 徐艳利, 李颖, 陈益平, 等. 重组人干扰素α2b喷雾剂治疗小儿手足口病有效性和安全性的多中心对照临床研究[J]. 中华传染病杂志, 2018, 36(2):101-106.
[12] ATHALE S, BANCHEREAU R, THOMPSON-SNIPES L A, et al. Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets[J]. Sci Transl Med, 2017, 9(382):eaaf9194.
[13] 康利娜, 路素坤, 郝恒瑞, 等. 重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎的疗效及对肺功能和炎性因子的影响[J]. 中国妇幼保健, 2018, 33(7): 1530-1533.
[14] 崔利丹, 金志鹏, 王琪, 等. 同剂量重组人干扰素α2b雾化吸入治疗儿童病毒性肺炎的疗效及其对血清炎性因子和免疫功能的影响[J]. 儿科药学杂志, 2018, 24(10): 29-33.
[15] 许光锋.重组人干扰素α-2b喷雾剂联合奥司他韦治疗甲型流感的疗效评价[J]. 山西卫生健康职业学院学报,2020,30(4):53-55.
[16] 张士红. 磷酸奥司他韦口服联合重组人干扰素α2b注射液雾化对儿童流行性感冒治疗的临床效果研究[J]. 世界最新医学信息文摘,2020,95(1):97-98.
[17] 郭玉峰. 不同剂量重组人干扰素α1b雾化吸入对儿童流行性感冒的临床效果研究[J]. 中国医药指南, 2020, 18(10):15-17.